Literature DB >> 30671778

Vitamin D is not associated with HIV-associated neurocognitive disorder in Rakai, Uganda.

Deanna Saylor1,2, Gertrude Nakigozi3, Carlos A Pardo4, Alice Kisakye3, Anupama Kumar4, Noeline Nakasujja5, Kevin R Robertson6, Ronald H Gray7, Maria J Wawer7, Ned Sacktor4.   

Abstract

We investigated whether vitamin D is associated with HIV-associated neurocognitive disorder (HAND). HIV-infected (HIV+) antiretroviral therapy (ART)-naïve adults in rural Uganda underwent a neurocognitive battery for determination of HAND stage at baseline and after 2 years. Baseline serum 25-hydroxyvitamin D (25OH-D) and serum and cerebrospinal fluids (CSF) vitamin D-binding protein (VDBP) were obtained. Of the 399 participants, 4% (n = 16) were vitamin D deficient (25OH-D < 20 ng/mL). There was no association between 25OH-D, serum or CSF VDBP, and HAND stage at baseline or follow-up. Future studies in a population with higher levels of vitamin D deficiency may be warranted.

Entities:  

Keywords:  Africa; Epidemiology; HIV; HIV-associated neurocognitive disorder; Vitamin D

Mesh:

Substances:

Year:  2019        PMID: 30671778      PMCID: PMC6635069          DOI: 10.1007/s13365-018-00719-6

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  20 in total

1.  Updated research nosology for HIV-associated neurocognitive disorders.

Authors:  A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna
Journal:  Neurology       Date:  2007-10-03       Impact factor: 9.910

2.  Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.

Authors:  Jan Jessen Krut; Henrik Zetterberg; Kaj Blennow; Paola Cinque; Lars Hagberg; Richard W Price; Marie Studahl; Magnus Gisslén
Journal:  J Neurol       Date:  2012-10-09       Impact factor: 4.849

3.  Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.

Authors:  Iain C Anthony; Katherine E Norrby; Tommy Dingwall; Frances W Carnie; Tracey Millar; Juan Carlos Arango; Roy Robertson; Jeanne E Bell
Journal:  Brain       Date:  2010-12       Impact factor: 13.501

4.  HIV-1 Tat inhibits neprilysin and elevates amyloid beta.

Authors:  Hans C Rempel; Lynn Pulliam
Journal:  AIDS       Date:  2005-01-28       Impact factor: 4.177

5.  Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology.

Authors:  M Moon; H Song; H J Hong; D W Nam; M-Y Cha; M S Oh; J Yu; H Ryu; I Mook-Jung
Journal:  Cell Death Differ       Date:  2012-12-21       Impact factor: 15.828

6.  CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease.

Authors:  D B Clifford; A M Fagan; D M Holtzman; J C Morris; M Teshome; A R Shah; J S K Kauwe
Journal:  Neurology       Date:  2009-11-11       Impact factor: 9.910

7.  Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment.

Authors:  Wojciech Rozek; Mary Ricardo-Dukelow; Sondra Holloway; Howard E Gendelman; Valerie Wojna; Loyda M Melendez; Pawel Ciborowski
Journal:  J Proteome Res       Date:  2007-10-12       Impact factor: 4.466

8.  Vitamin D and HIV progression among Tanzanian adults initiating antiretroviral therapy.

Authors:  Christopher R Sudfeld; Molin Wang; Said Aboud; Edward L Giovannucci; Ferdinand M Mugusi; Wafaie W Fawzi
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 9.  Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

Authors:  Brian Giunta; Jared Ehrhart; Demian F Obregon; Lucy Lam; Lisa Le; JingJi Jin; Francisco Fernandez; Jun Tan; R Douglas Shytle
Journal:  Mol Brain       Date:  2011-06-07       Impact factor: 4.041

10.  Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality.

Authors:  Saurabh Mehta; Edward Giovannucci; Ferdinand M Mugusi; Donna Spiegelman; Said Aboud; Ellen Hertzmark; Gernard I Msamanga; David Hunter; Wafaie W Fawzi
Journal:  PLoS One       Date:  2010-01-19       Impact factor: 3.240

View more
  2 in total

1.  Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.

Authors:  Leah H Rubin; Deanna Saylor; Gertrude Nakigozi; Noeline Nakasujja; Kevin Robertson; Alice Kisakye; James Batte; Richard Mayanja; Aggrey Anok; Sarah M Lofgren; David R Boulware; Raha Dastgheyb; Steven J Reynolds; Thomas C Quinn; Ronald H Gray; Maria J Wawer; Ned Sacktor
Journal:  J Neurovirol       Date:  2019-06-19       Impact factor: 2.643

2.  Prevalence of Severe Neurocognitive Impairment and Its Association with Socio-Demographics and Functionality Among Ugandan Older Persons: A Hospital-Based Study.

Authors:  Letizia Maria Atim; Mark Mohan Kaggwa; Mohammed A Mamun; Scholastic Ashaba; Samuel Maling
Journal:  Clin Interv Aging       Date:  2021-07-22       Impact factor: 4.458

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.